Kymera Therapeutics (NASDAQ:KYMR) Hits New 1-Year Low - Here's What Happened

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $19.75 and last traded at $21.91, with a volume of 832315 shares. The stock had previously closed at $22.07.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KYMR. Stephens restated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Leerink Partners reissued an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Price Performance

The company has a fifty day moving average of $31.62 and a 200 day moving average of $39.76. The firm has a market capitalization of $1.57 billion, a P/E ratio of -10.31 and a beta of 2.22.

Remove Ads

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 over the last 90 days. Company insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares in the last quarter. State of Wyoming bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $45,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $55,000. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after buying an additional 752 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Kymera Therapeutics by 3,851.5% during the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock worth $183,000 after acquiring an additional 6,509 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.